Abivax Presents First Half 2025 Financial Results

Core Viewpoint - Abivax SA reported a significant decline in total operating income and an increase in operating loss for the first half of 2025, highlighting challenges in its financial performance while continuing to advance its clinical programs [2][3][5]. Financial Highlights - Total operating income for the first half of 2025 was €2.1 million, down from €6.8 million in the same period of 2024, representing a decrease of €4.7 million [3][5]. - Total operating expenses increased, with research and development (R&D) costs rising to €77.9 million from €64.7 million, an increase of €13.2 million [3][5]. - The operating loss for the first half of 2025 was €93.7 million, compared to €80.0 million in the first half of 2024, reflecting an increase of €13.7 million [3][5]. Cash Position - As of June 30, 2025, the company's net financial position was €(20.2) million, a decrease of €73.6 million from €53.4 million at the end of 2024 [3][5]. - Available cash and cash equivalents decreased to €60.9 million from €144.2 million, a reduction of €83.3 million [3][5]. Recent Developments - On July 28, 2025, Abivax completed a public offering that raised approximately $747.5 million (about €637.5 million) before expenses, which is expected to support its financial needs [5][6]. - The company anticipates that its existing cash and the proceeds from the public offering will fund its operations into the fourth quarter of 2027 [7]. Clinical Programs - Abivax's lead drug candidate, obefazimod, is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis, indicating ongoing commitment to its therapeutic development [8].